Related Experiment Video

Updated: Jan 3, 2026

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
08:04

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons

Published on: June 6, 2025

1.3K

Clinical and genetic features in pyridoxine-dependent epilepsy: a Chinese cohort study

Xianru Jiao1, Jiao Xue1, Pan Gong1

  • 1Department of Pediatrics, Peking University First Hospital, Beijing, China.

Developmental Medicine and Child Neurology
|November 19, 2019
PubMed

Insights

Pyridoxine-dependent epilepsy (PDE) presents with diverse seizures and genetic variants. Most patients respond well to pyridoxine treatment, highlighting its therapeutic role.

Area of Science:

  • Epilepsy genetics
  • Neurogenetics
  • Clinical neurology

Background:

  • Pyridoxine-dependent epilepsy (PDE) is a rare inherited metabolic disorder.
  • Characterizing clinical and genetic features is crucial for diagnosis and management.

Purpose of the Study:

  • To define the clinical and genetic spectrum of pyridoxine-dependent epilepsy (PDE).
  • To assess treatment response in a large patient cohort.

Main Methods:

  • Retrospective analysis of clinical and genetic data from 33 PDE patients.
  • Genetic sequencing to identify variants in ALDH7A1 and PLPBP genes.

Main Results:

  • Focal seizures were predominant (32/33 patients).
  • Identified 26 ALDH7A1 and 4 PLPBP variants, with 18 novel.
  • Pyridoxine treatment controlled seizures in most patients, with exceptions in cases of large deletions.

Conclusions:

  • PDE exhibits varied clinical and genetic presentations.
  • Pyridoxine monotherapy is effective for most PDE patients.
  • EEG findings correlate with pyridoxine therapy status.
Abstract

More Related Videos

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.3K
Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

976

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.3K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.1K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
763
Pedigree Analysis01:35

Pedigree Analysis

Overview
88.6K
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
663